Comparison of DOR and DRV/r in DRIVE-FORWARD Study
DRIVE-FORWARD Study compared the efficacy of doravirine (DOR) with darunavir/ritonavir (DRV/r) in treatment-naive HIV patients. The study aimed to show non-inferiority of DOR based on virologic response at week 48. Results indicated similar virologic response rates between DOR and DRV/r groups, with
0 views • 10 slides
Efficacy of Ombitasvir-Paritaprevir-Ritonavir and Dasabuvir with Ribavirin in Liver Transplant Recipients with Recurrent HCV GT1
The CORAL-I trial evaluated the safety and efficacy of the 3D regimen (ombitasvir-paritaprevir-ritonavir + dasabuvir) combined with ribavirin for 24 weeks in liver transplant recipients with recurrent HCV genotype 1. The study included treatment-naive individuals after transplantation, with specific
0 views • 8 slides